PHAT vs STTK
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PHAT · Phathom Pharmaceuticals$4.66 ▼ 8.27%
STTK · Shattuck Labs$4.46 ▼ 1.98%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PHAT -68.6%
- STTK +116.5%
Head to head
| Metric | PHAT | STTK |
|---|---|---|
| Price | $4.66 | $4.46 |
| Change today | ▼ 8.27% | ▼ 1.98% |
| Market cap | $378.82M | $454.22M |
| Return, 3 months | -46.2% | -43.5% |
| Return, year to date | -71.9% | +22.2% |
| Return, 1 year | -68.9% | +119.7% |
| P/E (TTM) | – | – |
| P/B | -1.1 | 2.3 |
| P/E percentile vs own 5y | 4th | 10th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +71.1% | -100.0% |
| Net profit growth (YoY) | +53.6% | -150.6% |
| Gross margin | 80.7% | – |
| Operating margin | -9.3% | – |
| Net margin | -30.2% | – |
| Return on equity | – | -47.2% |
| Analyst target vs. price | +262.7% | +242.8% |
| Analyst buy share | 83% | 100% |
| RSI (14) | 31 | 35 |
| 30-day volatility | 98.0% | 73.9% |
| Max drawdown, 1 year | -74.2% | -50.5% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- STTK is the largest of the group by market value.
- STTK has returned the most over the past year.
- PHAT is growing revenue fastest.
- STTK has been the calmest stock over the last 30 days.